Weiss Ratings Reaffirms Sell (E+) Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “sell (e+)” rating reissued by Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Other research analysts have also issued reports about the company. Wells Fargo & Company reduced their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, August 7th. HC Wainwright upgraded Zentalis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 7th. Finally, Wall Street Zen upgraded Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $5.84.

Zentalis Pharmaceuticals Trading Up 10.4%

ZNTL stock opened at $1.81 on Wednesday. The business’s 50-day moving average price is $1.58 and its two-hundred day moving average price is $1.43. The firm has a market cap of $130.57 million, a PE ratio of -0.80 and a beta of 1.77. Zentalis Pharmaceuticals has a 1-year low of $1.01 and a 1-year high of $4.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.19. On average, analysts forecast that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Institutional Trading of Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ZNTL. Millennium Management LLC increased its position in shares of Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after acquiring an additional 2,111,951 shares during the last quarter. Acadian Asset Management LLC increased its position in Zentalis Pharmaceuticals by 150.6% during the first quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company’s stock worth $4,244,000 after buying an additional 1,606,802 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in Zentalis Pharmaceuticals during the second quarter worth approximately $1,126,000. Peapod Lane Capital LLC acquired a new position in Zentalis Pharmaceuticals during the first quarter worth approximately $888,000. Finally, Tybourne Capital Management HK Ltd. increased its position in Zentalis Pharmaceuticals by 53.7% during the second quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company’s stock worth $1,715,000 after buying an additional 516,666 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.